newsfilter
← Latest News
Business Wire·

Natera and Aveta Biomics Announce Strategic Partnership Supporting Global Phase 3 Registrational Trial of APG-157 in Head and Neck Cancer

Signatera™ will be used to evaluate molecular response to APG-157 in the neoadjuvant, induction, and adjuvant settingsNatera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, and Aveta